These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 9760805)
1. [Granulocyte macrophage-colony stimulating factor (GM-CSF) in diagnosis and monitoring of non-small cell lung cancer]. Mroczko B; Szmitkowski M; Furman M; Czygier M Pol Arch Med Wewn; 1998 Mar; 99(3):195-202. PubMed ID: 9760805 [TBL] [Abstract][Full Text] [Related]
2. [Granulocyte colony stimulating factor (G-CSF) in diagnosis and monitoring of non-small-cell lung cancer (NSCLC)]. Mroczko B; Szmitkowski M; Czygier M Pol Arch Med Wewn; 2000; 103(3-4):163-8. PubMed ID: 11236243 [TBL] [Abstract][Full Text] [Related]
3. [Stem cell factor (SCF) in diagnosis and monitoring of non-small-cell lung cancer]. Mroczko B; Szmitkowski M; Czygier M Pol Arch Med Wewn; 1999 Mar; 101(3):213-8. PubMed ID: 10697397 [TBL] [Abstract][Full Text] [Related]
4. [Macrophage-colony stimulating factor (M-csf) in diagnostic and monitoring of non-small-cell lung cancer (NSCLC)]. Mroczko B; Szmitkowski M Pol Arch Med Wewn; 2001 Mar; 105(3):203-9. PubMed ID: 11680264 [TBL] [Abstract][Full Text] [Related]
5. Granulocyte-Colony stimulating factor and macrophage-colony stimulating factor in patients with non-small-cell lung cancer. Mroczko B; Szmitkowski M; Niklinski J Clin Chem Lab Med; 2001 May; 39(5):374-9. PubMed ID: 11434384 [TBL] [Abstract][Full Text] [Related]
6. Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumour markers for non-small-cell lung cancer. Mroczko B; Szmitkowski M; Niklinski J Clin Chem Lab Med; 1999 Oct; 37(10):959-62. PubMed ID: 10616749 [TBL] [Abstract][Full Text] [Related]
7. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer]. Mroczko B; Szmitkowski M; Czygier M Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186 [TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J Oncology; 2006; 70(2):115-25. PubMed ID: 16645324 [TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage-colony stimulating factor in patients with colorectal cancer. Mroczko B; Szmitkowski M; Okulczyk B; Piotrowski Z Folia Histochem Cytobiol; 2001; 39 Suppl 2():110-1. PubMed ID: 11820563 [TBL] [Abstract][Full Text] [Related]
10. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer. Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414 [TBL] [Abstract][Full Text] [Related]
11. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
12. Hematopoietic cytokines in the sera of patients with pancreatic cancer. Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207 [TBL] [Abstract][Full Text] [Related]
13. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
15. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
16. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Muley T; Dienemann H; Ebert W Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer. Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651 [TBL] [Abstract][Full Text] [Related]
19. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer. Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790 [TBL] [Abstract][Full Text] [Related]
20. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer. Chantapet P; Riantawan P; Lebnak P; Getngern P J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]